Top

Drugs & Aging

Published in:

01-06-2006 | Adis Drug Profile

Zoster Vaccine Live (Oka/Merck)

A Viewpoint by Anthony L. Cunningham

Author: Anthony L. Cunningham

Published in: Drugs & Aging | Issue 6/2006

Excerpt

Progress in the therapy of herpes zoster has stalled since the introduction of famciclovir and valaciclovir almost a decade ago. These drugs significantly reduced the incidence and duration of severe pain (postherpetic neuralgia; PHN) after herpes zoster if commenced within 72 hours. However, early treatment, higher doses or combination with corticosteroids have not further reduced the incidence or duration of such pain.[1‐3] …

The use of trade names is for product identification purposes only and does not imply endorsement.

Douglas MW, Johnson RW, Cunningham AL. Tolerability of treatments for postherpetic neuralgia. Drug Saf 2004; 27(15): 1217–33PubMedCrossRef

Wood MJ, Johnson RW, McKendrick MW, et al. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994 Mar 31; 330(13): 896–900PubMedCrossRef

Whitley RJ, Weiss H, Gnann JW Jr, et al. Acyclovir with and without prednisone for the treatment of herpes zoster: a randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med 1996 Sep 1; 125(5): 376–83PubMed

Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005 Jun 2; 352(22): 2271–84PubMedCrossRef

Levin MJ, Murray M, Rotbart HA, et al. Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis 1992 Aug; 166(2): 253–9PubMedCrossRef

Hata A, Asanuma H, Rinki M, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002 Jul 4; 347(1): 26–34PubMedCrossRef

Title: Zoster Vaccine Live (Oka/Merck)
A Viewpoint by Anthony L. Cunningham
Author: Anthony L. Cunningham
Publication date: 01-06-2006
Publisher: Springer International Publishing
Published in: Drugs & Aging / Issue 6/2006
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI: https://doi.org/10.2165/00002512-200623060-00008

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2006

Practical Considerations for the Treatment of Elderly Patients with Migraine

Treating Asthma in the Older Patient

Homocysteine Lowering with Folic Acid and Vitamin B Supplements